Cite
MLA Citation
Dickran Kazandjian et al.. “Benefit-Risk Summary of Crizotinib for the Treatment of Patients With ROS1 Alteration-Positive, Metastatic Non-Small Cell Lung Cancer.” Oncologist, vol. 21, 2016, pp. 974–980. http://access.bl.uk/ark:/81055/vdc_100151233965.0x000031